Evolus Inc. (NASDAQ: EOLS), which is trying to compete with Allergan’s Botox, said Lauren Silvernail will retire as chief financial officer, effective May 31.
The Newport Beach-based company said it’s searching for her successor.
“Lauren has been instrumental in helping us build this company from a development stage organization to a fast-growing and well-funded commercial business,” Chief Executive David Moatazedi said in a statement.
Most recently, she and the team negotiated a $125 million credit facility that is expected to fund Evolus through cash flow breakeven, which the company said removes “the need for further financing of its current operations.”
Evolus today also reported fourth-quarter revenue soared 68% to $34.7 million, confirming its preliminary report issued Jan. 26. Shares were relatively unchanged in after-hours trading around $9 and a $500 million market cap.
